These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3750040)

  • 1. [Immunologic aspects of erysipelas].
    Uzhinova EP; Gudina RV; Dovgaliuk TI
    Sov Med; 1986; (6):111-2. PubMed ID: 3750040
    [No Abstract]   [Full Text] [Related]  

  • 2. [The information value of immunological tests in predicting recurrences of erysipelas].
    Bala MA; Rychnev VE; Tret'iakova NV
    Vrach Delo; 1990 Jun; (6):118-20. PubMed ID: 2399705
    [No Abstract]   [Full Text] [Related]  

  • 3. Problems of erysipelas. 3. Streptococcal vaccine treatment of relapsing erysipelas.
    Korossy S; Rajka O; Böszörményi J; Gózony M
    Acta Med Acad Sci Hung; 1968; 25(1):51-61. PubMed ID: 5678738
    [No Abstract]   [Full Text] [Related]  

  • 4. [Inhibition of serum antibodies in patients with recurrent erysipelas].
    Frolov VM; Rychnev VE; Zhuravleva NV
    Klin Med (Mosk); 1985 May; 63(5):91-5. PubMed ID: 4046519
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of phlegmonous and necrotic forms of erysipelas].
    Kuznetsov RV; Klokova RD; Myshkina AK
    Vestn Khir Im I I Grek; 1986 Jun; 136(6):72-5. PubMed ID: 3750717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of sodium nucleinate on the effectiveness of antibiotic therapy of erysipelas].
    Frolov VM; Rychnev VE; Peresadin NA
    Antibiotiki; 1984 Feb; 29(2):132-5. PubMed ID: 6703667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal antibodies in studying indices of cellular immunity in patients with erysipelas].
    Frolov VM; Gaĭdash IS; Peresadin NA; Baskakov IN
    Lab Delo; 1989; (6):71-2. PubMed ID: 2474717
    [No Abstract]   [Full Text] [Related]  

  • 8. [The effect of vilozen on the immune status of erysipelas patients and the prospects for its use for the immune rehabilitation of convalescents].
    Frolov VM; Peresadin NA; Pinskiĭ LL; Korobka IuN
    Lik Sprava; 1992; (11-12):102-4. PubMed ID: 1292201
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prognostic value of studying indices of nonspecific resistance and humoral immunity in patients with erysipelas].
    Kriukova SA; Panichkina LN
    Lab Delo; 1985; (9):555-6. PubMed ID: 2415766
    [No Abstract]   [Full Text] [Related]  

  • 10. [Nonspecific resistance of the body in erysipelas].
    Nagoev BS
    Sov Med; 1988; (4):25-7. PubMed ID: 3406817
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cellular immunity in patients with frequently recurring erysipelas].
    Frolov VM; Rychnev VE
    Klin Med (Mosk); 1986 Mar; 64(3):55-60. PubMed ID: 3487002
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cellular and humoral immunity in erysipelatous inflammation].
    Frolov VM; Rychnev VE; Azarin IG; Peresadin NA
    Vrach Delo; 1983 Dec; (12):97-100. PubMed ID: 6230799
    [No Abstract]   [Full Text] [Related]  

  • 13. Leukocyte migration test in recurrent erysipelas.
    Dobozy A; Schneider I; Hunyadi J; Simon N
    Acta Derm Venereol; 1973; 53(1):35-8. PubMed ID: 4120805
    [No Abstract]   [Full Text] [Related]  

  • 14. [Role of circulating immune complexes in patients with erysipelas].
    Frolov VM; Rychnev VE; Frolov AF; Bala MA
    Sov Med; 1986; (7):114-6. PubMed ID: 3764554
    [No Abstract]   [Full Text] [Related]  

  • 15. [Predisposing and triggering factors in erysipelas].
    Santos I; Andrade Lima MB; Andrade Lima BP
    Med Cutan Ibero Lat Am; 1984; 12(5):399-402. PubMed ID: 6396465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contribution to the pathogenesis of recurrent erysipelas].
    Pîrvu C; Serban I; Cîmpeanu M
    Med Interna (Bucur); 1969 Feb; 21(2):191-6. PubMed ID: 4180975
    [No Abstract]   [Full Text] [Related]  

  • 17. [The dynamics of the immunological indices during the treatment of recurrent erysipelas with the new immunostimulant bemitil].
    Ratnikova LI
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Sep; (9):56-8. PubMed ID: 1759524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinic-laboratory characteristics of recurrence erysipelas].
    Rychnev VE; Frolov VM; Shlykova SI; Peresadin NA; Zeĭtlenok DIu
    Sov Med; 1982; (3):102-4. PubMed ID: 6179165
    [No Abstract]   [Full Text] [Related]  

  • 19. [Characteristics of the clinical course of erysipelas and various indicators of nonspecific resistance in middle-aged patients].
    Kriukova ZV; Panichkina LN; Kriukova SA
    Vestn Dermatol Venerol; 1984 Aug; (8):48-50. PubMed ID: 6485539
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinico-immunological evaluation of antibiotic thereapy and prevention of frequent recurrences of erysipelas].
    Cherkasov VL; Iakhontova NK; Chistenkov NA
    Klin Med (Mosk); 1974 Feb; 52(2):52-7. PubMed ID: 4466916
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.